Cancer might be the mother of all pharmaceutical opportunities for the 21st century. Advances in biology over the past 40 years have ushered in a wave of targeted therapies that have proven in some cases to be more effective and more lucrative than traditional chemotherapy and radiation treatments. Drugmakers are now testing some 860 cancer drugs in clinical trials and pursuing a global cancer market worth an estimated $84 billion by 2012.
Enormous challenges remain in a field where only one out of every 10 drug candidates navigates the required clinical trials, and successful drugs often only help one-fourth of patients. Yet many of the most creative advances in the field are coming from New England. We will convene some of the leaders who are crafting these new strategies for fighting this complex and deadly disease.
Deborah Dunsire, CEO, Millennium: The Takeda Oncology Company
Tyler Jacks, Director, David H. Koch Institute for Integrative Cancer Research
Confirmed speakers include:
Alexis Borisy, CEO, Foundation Medicine, Entrepreneur-in-Residence, Third Rock Ventures
Doug Fambrough, CEO, Dicerna Therapeutics
Mark Goldsmith, CEO, Constellation Pharmaceuticals
Tuan Ha-Ngoc, CEO, Aveo Pharmaceuticals
Mike Huckman, SVP, Director of Media Strategy, MS&L
Dave Okrongly, CEO, Quanterix
Adelene Perkins, CEO, Infinity Pharmaceuticals
Nancy Simonian, Chief Medical Officer, Millennium: The Takeda Oncology Company
Sylvia Pagán Westphal, Columnist, Xconomy
Registration: 1:45 – 2:30 pm
Program: 2:30 – 6:00 pm
Networking reception: 6:00 – 7:00 pm
Saver Rate (ends October 6): $295
Regular Registration: $350
Walk-in Registration: $450
Student Registration: $95
Student scholarships available through the Stay in MA program.
Tickets are transferable but not refundable.
To inquire about press registration, e-mail firstname.lastname@example.org.